New drug vs standard chemo for advanced cervical cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called 9MW2821 against standard chemotherapy options for cervical cancer that has come back or spread. The goal is to see if the new drug works better than the usual treatments, and you must have already tried a platinum-based chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have cervical cancer (squamous cell, HPV-related adenocarcinoma, or adenosquamous type) that has come back or spread and cannot be treated with surgery or radiation.
- You have already received chemotherapy with a platinum drug (like cisplatin or carboplatin) for your advanced cancer, and it has stopped working or you couldn't continue.
- You are able to take care of yourself (fully active or able to do light work).
- You have not had more than 2 prior treatments for your advanced cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SYS6002 (an antibody-drug conjugate that targets cancer cells) against standard chemotherapy for cervical cancer that has spread or returned after prior treatment. The goal is to see if it can shrink tumors and help you live longer, possibly with fewer side effects.
This trial tests whether adding a drug called CB-839 to standard chemoradiation (cisplatin and radiation) can improve outcomes for people with advanced cervical cancer when it cannot be treated with surgery. It aims to see if this combination is safe and effective.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This trial tests a combination of new immunotherapy drugs (LB1410 and maybe LB4330) with lenvatinib (a targeted therapy) in patients with advanced cervical cancer that came back or spread. The goal is to see if this combo shrinks tumors or slows the cancer better than standard options.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
This trial tests a new drug, 9MW2821, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after previous treatments. It aims to see if the new drug works better.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.